Biotech companies in Scotlands thriving bio-based manufacturing have been invited to apply for up to £1m funding within the Launchpad programme.
Swiss Memo Therapeutics AG will use CHF25m raised in a new Series C financing to complete a Phase II study with Anti-BKV for prevention of virus-induced graft damage.
Researchers led by Wolfgang Enard from LMU Munich have identified a microRNA-based mechanism that drives atherosclerosis by weakening the integrity of blood vessel walls.
AstraZeneca plc has paid French cancer cell therapy developer Cellectis SA US$25m upfront and US$220m in equity in an US$2.2bn R&D deal for up to ten cell and gene therapies.
Italian pharma company Alfasigma SpA has signed a letter of intent to acquire the filgotinib business from Galapagos.
Raising $356m through a new Clinical Co-Development Co-Investment Fund (CCD-CIF), Carlyle-subsidiary Abingworth has extended its capital base for late-stage clinical bio-pharma programmes.
By mapping out associations between human protein networks and herbs used in traditional Chinese medicine (TCM), a Chinese-Bulgarian team can predict relief on various disease symptoms.
BioNtech SE has reported preliminary Phase I/II results with BNT211-01 (NEO-PTC-01) and CarVAC at ESMO conference in Madrid
Analysts describe as sporting the €7.1bn for Roche AG’s acquisition of Roivant subsidiary Telavant Holdings.
In an effort to address the global health threat of antimicrobial resistance (AMR), Innovate UK, LifeArc, and Medicines Discovery Catapult have jointly launched the PACE (Pathways to Antimicrobial Clinical Efficacy) initiative. With £30m (around €34,5m) in funding, PACE aims to support early-stage innovations aimed at countering AMR.